Healthcare Services

Global Rubella Diagnostic Testing Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Rubella Diagnostic Testing Market Over The Period 2026–2030?

The rubella diagnostic testing market size has experienced robust expansion in recent years. This market is projected to expand from $1.39 billion in 2025 to $1.48 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.5%. Historically, this market’s growth has been driven by the expansion of routine viral screening programs, increased awareness of congenital rubella syndrome, the availability of serological testing kits, the growth in diagnostic laboratory networks, and the adoption of immunoassay technologies.

The rubella diagnostic testing market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $1.89 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.4%. This expansion during the projection period stems from heightened investments in sophisticated diagnostic platforms, an elevated emphasis on maternal health screening, the spread of automated laboratory testing, a wider uptake of point-of-care diagnostics, and the reinforcement of infectious disease surveillance systems. Significant developments expected over the forecast horizon involve the increased utilization of molecular diagnostic techniques, a greater application of PCR-based rubella testing, an escalating need for prenatal screening, the broadening of high-sensitivity immunoassays, and a heightened emphasis on identifying diseases early.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19177&type=smp

What Drivers Are Expected To Influence The Rubella Diagnostic Testing Market During The Forecast Period?

The projected increase in viral infection cases is expected to accelerate the expansion of the rubella diagnostic testing market. Viral infections are illnesses caused by viruses, which are tiny infectious agents capable of replicating only within the living cells of an organism. This rise in viral infection incidents is linked to increased global travel, facilitating the transboundary spread of viruses, and climate change, which alters vector habitats and extends the range of disease-carrying organisms. Rubella diagnostic testing plays a crucial role in early identification and management of rubella infections, thereby preventing complications, particularly for pregnant women, and assisting in outbreak containment to curb virus transmission. For instance, in December 2023, the National Health Service, a UK-based government department, reported that daily hospital admissions for flu averaged 234, indicating a 53% increase from the previous week, while hospital cases of norovirus grew by 15% to an average of 406 daily, reflecting a 28% increase from the same week last year. Therefore, the escalating prevalence of viral infections is a significant driver for the growth of the rubella diagnostic testing market.

How Is The Rubella Diagnostic Testing Market Divided Into Its Major Segments?

The rubella diagnostic testing market covered in this report is segmented –

1) By Diagnostic Technique: Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (Ria), Fluorescent Immunoassay (FIA), Other Diagnostic Techniques

2) By Age Group: Neonates, Teenagers, Adults

3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Public Health Laboratories, Other End Users

Subsegments:

1) By Latex Agglutination: Qualitative Latex Agglutination Tests, Quantitative Latex Agglutination Tests, Rapid Latex Agglutination Kits

2) By Enzyme Immunoassay (EIA): Direct EIA, Indirect EIA, Sandwich EIA, Competitive EIA

3) By Radioimmunoassay (RIA): Standard RIA, Modified RIA, Single-Antibody RIA

4) By Fluorescent Immunoassay (FIA): Direct FIA, Indirect FIA, Sandwich FIA

5) By Other Diagnostic Techniques: Polymerase Chain Reaction (PCR), Nucleic Acid Amplification Tests (NAAT), Microplate-Based Assays, Western Blotting

Which Market Trends Are Creating New Opportunities In The Rubella Diagnostic Testing Market?

Leading companies in the rubella diagnostic testing market are concentrating on developing innovative solutions, such as a rubella virus vaccine, to enhance diagnostic accuracy and improve preventive measures. The rubella virus vaccine provides immunity against rubella, often administered as part of the MMR or MMRV combination vaccines to prevent the disease and associated complications. For instance, in March 2023, Merck & Co., Inc., a US-based pharmaceutical company, received FDA approval for the intramuscular (IM) administration of Merck’s M-M-R II vaccine, which is vital in protecting against rubella, along with measles and mumps. This approval allows healthcare providers to administer the rubella vaccine via the IM route, making it consistent with other routinely recommended pediatric vaccines. Rubella vaccination is crucial for preventing outbreaks and safeguarding against the severe complications the virus can cause, particularly in pregnant women.

Who Are The Prominent Organizations Shaping The Rubella Diagnostic Testing Market?

Major companies operating in the rubella diagnostic testing market are Cardinal Health Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMérieux S.A., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., Meridian Bioscience Inc., Fortress Diagnostics Ltd., Mylab Discovery Solutions Pvt. Ltd., MP Biomedicals LLC, CTK Biotech Inc., ZEUS Scientific Inc., Creative Diagnostics, Arlington Scientific Inc., AccuBioTech Co. Ltd., Intec Products Inc., Vitrosens Biotechnology Ltd., Sprint Diagnostics Pvt. Ltd., InDevR Inc., Atlas Medical GmbH

Read the full rubella diagnostic testing market report here:

https://www.thebusinessresearchcompany.com/report/rubella-diagnostic-testing-global-market-report

Which Region Is Forecast To Lead The Rubella Diagnostic Testing Market In Terms Of Market Size?

North America was the largest region in the rubella diagnostic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rubella diagnostic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rubella Diagnostic Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19177&type=smp

Browse Through More Reports Similar to the Global Rubella Diagnostic Testing Market 2026, By The Business Research Company

Gastrointestinal Pathogen Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/gastrointestinal-pathogen-testing-global-market-report

Clinical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Hospital Acquired Infections Testing Kits Global Market Report

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795